Curis Stock Almost Doubles Crossing $2 Line

The age of therapeutics, biotech, and pharmacy will continue for long as COVID-19 is walking around the globe. Not only this virus bothers scientists to raise funds from optimistic investors. For instance, Curis focuses on cancer treatment to prolong patients’ lives. Therefore, NASDAQ: CRIS soared 41.86% to $1.22 on Tuesday increasing daily volume to 3,398,644 shares. Today before the market opens the stock grows at least by 80% that lets to surpass $2.

Q1 2020 revenue fell quarterly by $578k together with its cost. Gross profit for Q1 thus fell to $2,584,000 leading to an operating loss and zero EPS. Despite this fruitless news potential investors do not go away while fighting against cancer has been in the global trend for decades.

Curis is obviously overvalued in the market while actual capitalization isn’t a great number. Moreover, negative earnings still derive negative EPS, now at $-22.9720.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life

Alex Krakowsky has 979 posts and counting. See all posts by Alex Krakowsky